Swedish Orphan Biovitrum stock

SOBI · Nasdaq Stockholm · SEK

Compare Swedish Orphan Biovitrum
kr 480.20Change from previous close: +1.27%Absolute change: +kr 6.00

Close · November 16, 2026

Price history

+43.35% over the period

1 year: from kr 336.80 (November 17, 2025) to kr 482.80 (November 16, 2026), +43.35%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 16, 2026kr 482.80
October 30, 2026kr 490.20
September 30, 2026kr 440.40
August 31, 2026kr 449.80
July 31, 2026kr 470.60
June 30, 2026kr 462.00
May 29, 2026kr 442.20
April 30, 2026kr 427.80
March 31, 2026kr 392.20
February 27, 2026kr 395.40
January 30, 2026kr 337.00
December 30, 2025kr 332.80
November 28, 2025kr 338.80
November 17, 2025kr 336.80

At a glance

  • The company

    Biopharma company offering medicines for haematology, immunology and specialty care across Europe, North America, Middle East, Asia and Australia

  • Latest results

    Quarter to September 30, 2026 · EPS kr 6.89 (estimate kr 5.98)

TickerLandia's take on Swedish Orphan Biovitrum

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk lowkr 314.40
52-wk highkr 507.00

−5.29% from the 52-week high

Analysts · 12 analysts

Average targetkr 506.50+5.48% vs. price

Buy 6 · Hold 6 · Sell 0 · Buy

TickerLandia Fingerprint: Swedish Orphan Biovitrum

Compared with similar companies: high growth, strong momentum, and high profitability.

Financials and price compared with 39 companies in the drug manufacturers - specialty & generic industry, worldwide. Momentum and risk compared with 1,160 European stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

Swedish Orphan Biovitrum is in line with similar companies

Swedish Orphan Biovitrum's P/E (trailing 12 months): 25.4, in line with the median of a group of 11 similar companies (25.0).

Compared with 11 similar companies

Swedish Orphan Biovitrum's metrics compared with similar companies
MetricSwedish Orphan BiovitrumPosition in the groupBand
P/E (trailing 12 months)25.4Middle
Forward P/E30.9High
Operating margin30.9%High
ROE16.3%Middle
Debt/equity0.36Middle

Grey band: the middle half of the group; tick: the median; dot: Swedish Orphan Biovitrum. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

kr 9.12B

Latest quarter · Q3 2026

Net income

kr 2.35B

Latest quarter · Q3 2026

Quarterly net margin

25.8%

Latest quarter · Q3 2026

Numbers and valuation

Full valuation
Market cap
kr 167.11B
P/E
25.4
EPS
kr 18.94
Volume
435.42K
Daily trading
€21.63M
Dividend yield
0.00%

How Swedish Orphan Biovitrum is changing

All results
  • Revenue grew 13.1% a year on average over the last 5 years

  • Operating margin rose from 24.1% to 28.5%

  • Shares outstanding up 16.8% in 5 years

Returns

Swedish Orphan Biovitrum returns

kr 1,000 invested in Swedish Orphan Biovitrum 5 years ago, on November 16, 2021, would be worth kr 2,218 today: +121.79% in total, +17.27% per year. This is the price return only: dividends are excluded.

PeriodSwedish Orphan Biovitrumkr 1,000 becomes
1 month+10.63%kr 1,106
6 months+8.89%kr 1,089
Year to date+45.07%kr 1,451
1 year+43.35%kr 1,433
3 years+97.06%kr 1,971
5 years+121.79%kr 2,218
10 years+425.43%kr 5,254

Price only, without dividends. Calculate your investment

The chart in detail

Swedish Orphan Biovitrum: technical analysis

Swedish Orphan Biovitrum is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is 3.6% below its all-time closing high (kr 498.20, November 6, 2026).

Trend
Upward
RSI (14 sessions)
56
Between 30 and 70
vs 200-session average
+10.39%

Support and resistance

Price areas where Swedish Orphan Biovitrum has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. No resistance above: the price is near the highs of the year
  2. Last pricekr 480.20
  3. Supportkr 472.30−1.65%2 touches, last on August 28, 2026
  4. Supportkr 448.63−6.57%7 touches, last on September 18, 2026
  5. Supportkr 433.00−9.83%5 touches, last on September 24, 2026

Volatility and risk

Volatility (60 sessions, annualised)
25.9%
Largest fall in the last year
−14.63%

Close of November 16, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

Swedish Orphan Biovitrum: seasonality

Average monthly price change over 21 years

+5.8%Jan+0.9%Feb+2.6%Mar+4.8%Apr+0.2%May+0.3%Jun+0.6%Jul+1.6%Aug+4.1%Sep−2.3%Oct−1.0%Nov+0.2%Dec

Over the last 21 years, the strongest month for Swedish Orphan Biovitrum has been January: +5.81% on average, positive in 15 years out of 20. The weakest has been October: −2.31% on average, positive in 8 years out of 21. November, the current month, has been positive in 10 years out of 20 (−1.05% on average).

Show chart data
MonthAverageMedianPositive years
January+5.81%+6.77%15 of 20
February+0.90%+0.89%10 of 20
March+2.56%+2.07%14 of 20
April+4.79%+3.03%13 of 20
May+0.21%−0.67%9 of 20
June+0.27%+0.64%11 of 20
July+0.63%−0.80%9 of 20
August+1.64%+1.88%10 of 20
September+4.14%+1.09%10 of 20
October−2.31%−1.30%8 of 21
November−1.05%−0.19%10 of 20
December+0.22%−1.80%8 of 20

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

Swedish Orphan Biovitrum and its competitors

Its medicines are sold across Europe, North America, the Middle East, Asia and Australia. The company works in three segments, Haematology, Immunology and Specialty Care, and its portfolio centres on treatments for haemophilia, such as Alprolix, ALTUVOCT and Elocta/Eloctate, alongside Synagis for respiratory syncytial virus in infants, Kineret for inflammatory conditions including rheumatoid arthritis, and Zynlonta for adult patients with lymphoma. It also markets Doptelet, Gamifant and Orfadin, and develops drug substances for Pfizer's ReFacto AF/Xyntha.

Headquarters
Stockholm, Sweden
Employees
2,207
Founded
1939
Chief executive
Guido Oelkers
Swedish Orphan Biovitrum and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
Swedish Orphan BiovitrumSOBI$16.63B30.9%25.4+8.89%
IpsenIPN$15.16B27.4%26.9+0.84%
H. LundbeckHLUN.A$8.54B24.4%14.2+62.22%
HaleonHLN$40.03B23.5%19.2+4.15%
Sandoz GroupSDZ$43.66B9.3%72.3+29.20%
Galderma GroupGALD$53.24B19.1%66.0+21.93%

Same industry or related industries, similar size. Compare Swedish Orphan Biovitrum with its competitors · Full profile